Clinical trials show:

85% of users lost at least 5% of their body weight over 68 weeks.

66% lost more than 10%, 48% lost over 15%, and 30% achieved more than 20% weight loss.

After 4 Weeks – Some users notice a reduced appetite and minor weight loss.

After 3 Months – More significant weight loss may occur as the body adjusts to the medication.

After 6 Months – Many users experience a 10-15% weight reduction from their initial body weight.

After 1 Year – Studies show continued use can lead to sustained weight loss of up to 20%.

Treatment Progression

After 4 Weeks: Appetite suppression and initial weight loss may begin.

After 6 Months: Noticeable weight reduction, many users achieve significant fat loss.

After 1 Year: Sustained weight loss, improved blood sugar control and metabolic health.

Wegovy activates GLP-1 receptors, leading to:

Decreased hunger signals in the brain.

Slower stomach emptying, prolonging fullness.

Improved insulin response, regulating blood sugar and reducing cravings.

Wegovy is available in 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg doses.

Starting Dose:25mg once weekly.

Dose Escalation: Increase gradually every four weeks, up to a maintenance dose of 4mg weekly, as tolerated.

Administration: Inject subcutaneously (under the skin) in the abdomen, thigh, or upper arm at the same time each week.

Missed Dose: If missed, take it within 5 days; otherwise, skip it and continue as scheduled.